Table 1 Articles used for Aβ OR analyses in the Mild Cognitive Impairment (MCI) group

ADNI

ADNI

MCI

785

72.5 (7.5)

_amyloidPET (SUVR >1.11), CSF Aβ42 (<977 pg/mL)

57 (40)

48

unspecified dementia

Arruda, 2023 [33]

Florida Alzheimer’s Disease Research Center

MCI

91

72.7 (8.7)

_amyloidPET (v.r.^a)

22.9 (7.1)

n.d.

unspecified dementia

Balassa, 2014 [15]

Hospital Clinic Barcelona, Spain

MCI

51

57.9 (6)

CSF Aβ42 (<500 pg/mL)

31 (15.8)

31.6

(8 - 82)

unspecified dementia

Baldeiras, 2022 [34]

Coimbra University Hospital; Hospital de Braga; Unidade Local de Saude de Matosinhos; Centro Hospi- ´ talar Baixo Vouga; Hospital Egas Moniz; Hospital de Faro, Portugal

MCI

150

65.2 (8.7)

CSF Aβ42/40

ratio (<0.068)

n.d.^b

n.d. (12-50)

unspecified dementia

Bos, 2017 [35]

Alzheimer Center Limburg, LeARN, DESCRIPA cohort

Mixed^d

(56.5% MCI)

271

65.6 (7.7)

CSF Aβ42 (≤ 550 pg/ml)

30 (14.4)

n.d.

unspecified dementia

Cerami, 2015 [36]

San Raffael Inst. Milan, Italy

MCI

34

69.8 (5.7)

CSF Aβ42 (<515 pg/m)

29 (8.5)

29

(15 - 60)

unspecified dementia

de Wilde,

2019 [37]^c

Alzheimer Center and Department of Neurology, VU University Medical Center Amsterdam, Netherland

MCI

110

65.5 (7.5)

_amyloidPET (v.r.), CSF Aβ42 (<813 pg/mL)

n.d.

22.8

(13.2 - 32.4)

unspecified dementia

Eckerstrom, 2021 [38]

Goteborg MCI study

Mixed^d

(58.1% MCI)

420

64.2 (7.3)

CSF Aβ42 (≤482 ng/L)

31.6 (19)

n.d.

unspecified dementia

Frolich, 2017 [39]

DCN (Dementia Competence Network, German multicenter cohort study)

MCI

115

65.7 (9.3)

CSF Aβ42 (<600 pg/ml)

25.5 (9.8)

n.d.

unspecified dementia

Grontvedt, 2020 [14]

Department of Neurology, Univ. Hosp. Trondheim, Norway

MCI

57

64 (53 - 79)

CSF Aβ42 (<630 pg/ml)

n.d.

108

(72 - 120)

unspecified dementia

Groot, 2022 [40]

Malmö University Hospital, Sweden

MCI

147

72.1 (7.7)

CSF Aβ42/40

ratio (<0.07)

59.0 (25.1)

n.d.

unspecified dementia

Hanseeuw, 2021 [41]

Neurology Department, Saint-Luc University Hospital, Belgium

MCI

46

71.4 (7.5)

_amyloidPET (v.r.)

38.4 (15.6)

n.d.

unspecified dementia

Herukka, 2005 [42]

Neurologic Department at Kuopio University Hospital, Finland

MCI

66

70.4 (7.4)

CSF Aβ42 (<452 pg/mL)

n.d.

36

(6-144)

unspecified dementia

Jimenez Bonilla, 2019 [43]

Neurology, University Hospital ‘Marqués de Valdecilla’, University of Cantabria, Santander, Spain

MCI

14

67.1 (5.1)

_amyloidPET (v.r.)

60

60

unspecified dementia

Lopez, 2018 [44]

Ginkgo biloba memory study (GEM [Ginkgo Evaluation of Memory] Study, USA

Mixed^d

(19.1% MCI)

183

85.6 (2.9)

_amyloidPET (SUVR >1.57)

68.4 (20.4)

n.d.

unspecified dementia

Okello, 2009 [45]

Imperial College Healthcare NHS Trust [London], The National Hospital for Neurology and Neurosurgery [London], St. Margaret’s Hospital [Epping, and Victoria Hospital [Swindon], Turku Hosp., UK and Finland

MCI

31

69.4 (7.9)

_amyloidPET (v.r.)

36

36

unspecified dementia

Orellana, 2022 [46]

ACE Alzheimer Center Barcelona, Spain

MCI

647

72.8 (7.8)

CSF Aβ42/40

ratio (<0.069)

21 (10.8)

n.d.

unspecified dementia

Ortega, 2019 [47]

Hospital Santa Maria de Lleida, Spain

MCI

55

71.9 (6.7)

CSF Aβ42 (<450 pg/ml)

n.d.

24

(no inf.)

unspecified dementia

Riemenschneider, 2002 [48]

Department of Psychiatry, Pearth, Australia

MCI

28

69.2 (7.9)

CSF Aβ42 (<500 pg/mL)

18

18

unspecified dementia

Rizzi, 2020 [49]

Division of Geriatric Neurology, Neurology Service, Hospital de Clínicas de Porto Alegre, Rua Ramiro Barcelos, Brazil

MCI

31

67.4 (60 - 78)

CSF Aβ42 (<618.5 pg/mL)

60

60

AD dementia^e

Roberts, 2018 [50]

MCSA (Mayo Clinic Study of Aging)

MCI

179

78.3 (7.4)

_amyloidPET (SUVR >1.42)

45.6 (24)

n.d.

AD dementia^e

Villemagne, 2011 [51]

Austin Health Memory Disorders Clinic, USA

MCI

65

73.4 (8.5)

_amyloidPET (SUVR >1.5)

20 (3)

n.d.

unspecified dementia